Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. (Q43197450)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

0 references

C Lavini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M E van Linde

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

L J A Stalpers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J C Reijneveld

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

W R van Furth

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

D J Richel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Annals of Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1723-1727

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

Chemoradiotherapy in malignant glioma: standard of care and future directions

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Rechallenge with temozolomide in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Response criteria for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP591

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP591

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20064829%20AND%20SRC:MED&resulttype=core&format=json

release_6wqnuu344vandgiash5wuf4wwm

16 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6wqnuu344vandgiash5wuf4wwm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference